Within Group 2b cases, we confirmed the origin of two relevant TGVs: one germline ATM variant in a patient with papillary thyroid cancer and one somatic BAP1 variant in a patient with renal cell carcinoma. This evidence concerns the gene ATM and renal cell carcinoma.